The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F17%3A00098134" target="_blank" >RIV/00216224:14740/17:00098134 - isvavai.cz</a>
Výsledek na webu
<a href="http://mct.aacrjournals.org/content/16/10_Supplement/A34" target="_blank" >http://mct.aacrjournals.org/content/16/10_Supplement/A34</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1538-8514.SYNTHLETH-A34" target="_blank" >10.1158/1538-8514.SYNTHLETH-A34</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies
Popis výsledku v původním jazyce
It was shown that BCR inhibitors such as ibrutinib interrupt microenvironmental interactions and mobilize malignant B cells of chronic lymphocytic leukemia (CLL) from immune niches into the blood stream. It has been suggested that this mobilization will sensitize malignant B cells to other drugs, providing a possibility to introduce synthetically lethal combinations of drugs with an acceptable toxicity profile. This might be limited to a subgroup of CLL patients with specific underlying molecular mechanisms of disease biology or reaction to BCR inhibitors. The aim of this study was to test for the effect of ibrutinib on the expression of genes and activity of pathways that could be potentially targeted by clinically available drugs to achieve highly potent combinations.
Název v anglickém jazyce
The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies
Popis výsledku anglicky
It was shown that BCR inhibitors such as ibrutinib interrupt microenvironmental interactions and mobilize malignant B cells of chronic lymphocytic leukemia (CLL) from immune niches into the blood stream. It has been suggested that this mobilization will sensitize malignant B cells to other drugs, providing a possibility to introduce synthetically lethal combinations of drugs with an acceptable toxicity profile. This might be limited to a subgroup of CLL patients with specific underlying molecular mechanisms of disease biology or reaction to BCR inhibitors. The aim of this study was to test for the effect of ibrutinib on the expression of genes and activity of pathways that could be potentially targeted by clinically available drugs to achieve highly potent combinations.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30200 - Clinical medicine
Návaznosti výsledku
Projekt
<a href="/cs/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů